Search

Your search keyword '"Quesada, Jean-Louis"' showing total 311 results
Start Over Author "Quesada, Jean-Louis"
311 results on '"Quesada, Jean-Louis"'

7. Endovascular Thrombectomy for Acute Iliofemoral Deep Venous Thrombosis Through a Jugular Approach with a Rotational Device

Author

Thony, Frederic, Pernes, Jean-Marc, Menez, Caroline, Quesada, Jean-Louis, Heautot, Jean-François, Thouveny, Francine, Monnin-Bares, Valerie, Bellier, Alexandre, David, Arthur, Lablee, Alexandre, Bouvier, Antoine, Vernhet-Kovacsik, Helene, Douane, Frederic, Del Giudice, Costantino, Sapoval, Marc, Guillen, Kevin, Loffroy, Romaric, Finas, Mathieu, and Rodiere, Mathieu

Published
2023
Full Text
View/download PDF

18. Treatment of acute appendicitis in France by type of hospital: Patient profiles are different but practices and results are the same, a prospective cohort study of 1241 patients

Author

Barbois, Sandrine, Gaget, Olivier, Quesada, Jean-louis, Foote, Alison, Laverriere, Marie-Hélène, Abba, Julio, Charrière, Bérénice, Nzamushe, Jean-Robert, Pautrat, Karine, Tan, Virianne, Regimbeau, Jean-Marc, Abet, Emeric, Dubois, Joelle, Lermite, Emilie, Passot, Guillaume, Mauvais, François, Varatharajah, Sharmini, Bensignor, Thierry, Pirlet, Isabelle, Herrero, Astrid, Riboud, Romain, Blanc, Benjamin, Monneuse, Olivier, Merdrignac, Aude, Mechaoui, Hamida, Briennon, Xavier, Massalou, Damien, Dubuisson, Vincent, Moreno-Lopez, Nathan, Schwarz, Lilian, Atger, Jérôme, Vuagniaux, Aurélie, Pichot-Delahaye, Virginie, Rasata, Lala Julien, Mustafa, Samer Al, Villar, Frédéric, Allaoua, Smail, Putinier, Jean-Baptiste, Lakkis, Zaher, Bouteloup, Pierre-Yves, Malgoire, Jean-Yves, Mathonnet, Muriel, Varlet, François, Scalabre, Aurélien, Mutter, Didier, Frandon, Julien, Tidadini, Fatah, and Arvieux, Catherine

Published
2021
Full Text
View/download PDF

19. Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial)

Author

Verry, Camille, Dufort, Sandrine, Villa, Julie, Gavard, Marylaure, Iriart, Carole, Grand, Sylvie, Charles, Julie, Chovelon, Benoit, Cracowski, Jean-Luc, Quesada, Jean-Louis, Mendoza, Christophe, Sancey, Lucie, Lehmann, Audrey, Jover, Florence, Giraud, Jean-Yves, Lux, François, Crémillieux, Yannick, McMahon, Stephen, Pauwels, Petrus J., Cagney, Daniel, Berbeco, Ross, Aizer, Ayal, Deutsch, Eric, Loeffler, Markus, Le Duc, Géraldine, Tillement, Olivier, and Balosso, Jacques

Published
2021
Full Text
View/download PDF

20. SAME day amBulatory c (SAMBA): a multicenter, prospective, randomized clinical trial protocol.

Author

Arvieux, Catherine, Tidadini, Fatah, Barbois, Sandrine, Fontas, Eric, Carles, Michel, Gridel, Victor, Orban, Jean-Christophe, Quesada, Jean-Louis, Foote, Alison, Cruzel, Coralie, Anthony, Sabine, Bulsei, Julie, Hivelin, Céline, and Massalou, Damien

Subjects
AMBULATORY surgery, PATIENT satisfaction, LENGTH of stay in hospitals, INPATIENT care, INTERVENTIONAL radiology
Abstract

Background: A recent meta-analysis concluded that outpatient appendectomy appears feasible and safe, but there is a lack of high-quality evidence and a randomized trial is needed. The aim of this trial is to demonstrate that outpatient appendectomy is non-inferior to conventional inpatient appendectomy in terms of overall morbi-mortality on the 30th postoperative day (D30). Methods: SAMBA is a prospective, randomized, controlled, multicenter non-inferiority trial. We will include 1400 patients admitted to 15 French hospitals between January 2023 and June 2025. Inclusion criteria are patients aged between 15 and 74 years presenting acute uncomplicated appendicitis suitable to be operated by laparoscopy. Patients will be randomized to receive outpatient care (day-surgery) or conventional inpatient care with overnight hospitalization in the surgery department. The primary outcome is postoperative morbi-mortality at D30. Secondary outcomes include time from diagnosis to appendectomy, length of total hospital stay, re-hospitalization, interventional radiology, re-interventions until D30, conversion from outpatient to inpatient, and quality of life and patient satisfaction using validated questionnaires. Discussion: The SAMBA trial tests the hypothesis that outpatient surgery (i.e., without an overnight hospital stay) of uncomplicated acute appendicitis is a feasible and reliable procedure in establishments with a technical platform able to support this management strategy. Trial registration: ClinicalTrials.gov NCT05691348. Registered on 20 January 2023. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Prevalence of Drug Use in Ultra-Endurance Athletes

Author

Robach, Paul, primary, Trebes, Gilles, additional, Buisson, Corinne, additional, Mechin, Nathalie, additional, Mazzarino, Monica, additional, Garribba, Flaminia, additional, Roustit, Matthieu, additional, Quesada, Jean-Louis, additional, Lefèvre, Brice, additional, Giardini, Guido, additional, de Seigneux, Sophie, additional, Botré, Francesco, additional, and Bouzat, Pierre, additional

Published
2024
Full Text
View/download PDF

23. Prevalence of Drug Use in Ultraendurance Athletes.

Author

ROBACH, PAUL, TREBES, GILLES, BUISSON, CORINNE, MECHIN, NATHALIE, MAZZARINO, MONICA, GARRIBBA, FLAMÍNIA, ROUSTIT, MATTHIEU, QUESADA, JEAN-LOUIS, LEFÈVRE, BRICE, GIARDINI, GUIDO, DE SEIGNEUX, SOPHIE, BOTRÉ, FRANCESCO, and BOUZAT, PIERRE

Published
2024
Full Text
View/download PDF

25. Oncological outcomes and hospitalization cost of hyperthermic intraperitoneal chemotherapy (HIPEC) open and closed abdomen techniques: Results from two French expert centers

Author

Ezanno, Anne-Cécile, primary, Chkair, Sihame, additional, Quesada, Jean-Louis, additional, Abba, Julio, additional, Malgras, Brice, additional, Trilling, Bertrand, additional, Sage, Pierre-Yves, additional, Bouvet, Sophie, additional, Foote, Alison, additional, Aime, Adeline, additional, Glehen, Olivier, additional, Pocard, Marc, additional, Arvieux, Catherine, additional, and Tidadini, Fatah, additional

Published
2023
Full Text
View/download PDF

29. The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma

Author

Polena, Helena, Creuzet, Julie, Dufies, Maeva, Sidibé, Adama, Khalil-Mgharbel, Abir, Salomon, Aude, Deroux, Alban, Quesada, Jean-Louis, Roelants, Caroline, Filhol, Odile, Cochet, Claude, Blanc, Ellen, Ferlay-Segura, Céline, Borchiellini, Delphine, Ferrero, Jean-Marc, Escudier, Bernard, Négrier, Sylvie, Pages, Gilles, and Vilgrain, Isabelle

Published
2018
Full Text
View/download PDF

37. Intranasal sufentanil versus intravenous morphine for acute severe trauma pain: A double-blind randomized non-inferiority study

Author

Blancher, Marc, Maignan, Maxime, Clapé, Cyrielle, Quesada, Jean-Louis, Collomb-Muret, Roselyne, Albasini, François, Ageron, François-Xavier, Fey, Stephanie, Wuyts, Audrey, Banihachemi, Jean-Jacques, Bertrand, Barthelemy, Lehmann, Audrey, Bollart, Claire, Debaty, Guillaume, Briot, Raphaël, and Viglino, Damien

Subjects
Acute pain -- Drug therapy -- Patient outcomes, Sufentanil -- Dosage and administration -- Comparative analysis -- Patient outcomes, Morphine -- Dosage and administration -- Comparative analysis -- Patient outcomes, Pain management, Physicians, Medical research, Anoxemia, Analgesia, Biological sciences
Abstract

Background Intravenous morphine (IVM) is the most common strong analgesic used in trauma, but is associated with a clear time limitation related to the need to obtain an access route. The intranasal (IN) route provides easy administration with a fast peak action time due to high vascularization and the absence of first-pass metabolism. We aimed to determine whether IN sufentanil (INS) for patients presenting to an emergency department with acute severe traumatic pain results in a reduction in pain intensity non-inferior to IVM. Methods and findings In a prospective, randomized, multicenter non-inferiority trial conducted in the emergency departments of 6 hospitals across France, patients were randomized 1:1 to INS titration (0.3 [mu]g/kg and additional doses of 0.15 [mu]g/kg at 10 minutes and 20 minutes if numerical pain rating scale [NRS] > 3) and intravenous placebo, or to IVM (0.1 mg/kg and additional doses of 0.05 mg/kg at 10 minutes and 20 minutes if NRS > 3) and IN placebo. Patients, clinical staff, and research staff were blinded to the treatment allocation. The primary endpoint was the total decrease on NRS at 30 minutes after first administration. The prespecified non-inferiority margin was -1.3 on the NRS. The primary outcome was analyzed per protocol. Adverse events were prospectively recorded during 4 hours. Among the 194 patients enrolled in the emergency department cohort between November 4, 2013, and April 10, 2016, 157 were randomized, and the protocol was correctly administered in 136 (69 IVM group, 67 INS group, per protocol population, 76% men, median age 40 [IQR 29 to 54] years). The mean difference between NRS at first administration and NRS at 30 minutes was -4.1 (97.5% CI -4.6 to -3.6) in the IVM group and -5.2 (97.5% CI -5.7 to -4.6) in the INS group. Non-inferiority was demonstrated (p < 0.001 with 1-sided mean-equivalence t test), as the lower 97.5% confidence interval of 0.29 (97.5% CI 0.29 to 1.93) was above the prespecified margin of -1.3. INS was superior to IVM (intention to treat analysis: p = 0.034), but without a clinically significant difference in mean NRS between groups. Six severe adverse events were observed in the INS group and 2 in the IVM group (number needed to harm: 17), including an apparent imbalance for hypoxemia (3 in the INS group versus 1 in the IVM group) and for bradypnea (2 in the INS group versus 0 in the IVM group). The main limitation of the study was that the choice of concomitant analgesics, when they were used, was left to the discretion of the physician in charge, and co-analgesia was more often used in the IVM group. Moreover, the size of the study did not allow us to conclude with certainty about the safety of INS in emergency settings. Conclusions We confirm the non-inferiority of INS compared to IVM for pain reduction at 30 minutes after administration in patients with severe traumatic pain presenting to an emergency department. The IN route, with no need to obtain a venous route, may allow early and effective analgesia in emergency settings and in difficult situations. Confirmation of the safety profile of INS will require further larger studies. Trial registration ClinicalTrials.gov NCT02095366. EudraCT 2013-001665-16., Author(s): Marc Blancher 1,*, Maxime Maignan 1,2, Cyrielle Clapé 1, Jean-Louis Quesada 3, Roselyne Collomb-Muret 1, François Albasini 4, François-Xavier Ageron 5, Stephanie Fey 6, Audrey Wuyts 7, Jean-Jacques Banihachemi [...]

Published
2019
Full Text
View/download PDF

38. Oncological Outcomes After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Peritoneal Carcinomatosis.

Author

Tidadini, Fatah, Abba, Julio, Quesada, Jean-Louis, Trilling, Bertrand, Bonne, Aline, Foote, Alison, Faucheron, Jean-Luc, and Arvieux, Catherine

Abstract

Background: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new surgical technique for the treatment of initially unresectable peritoneal carcinomatosis (PC). Our objective was to assess its oncological outcomes. Methods: Between July 2016 and September 2020, data from 100 PIPAC procedures with oxaliplatin or doxorubicin-cisplatin in 49 patients with PC (all etiologies) were analyzed. We studied the evolution of the peritoneal cancer index (PCI), the need for radical surgery (R0), and overall survival (OS). Results: The patients' median age was 65 (59; 71) years, and 55.1% were women. Median PIPAC procedures per patient were 2 (1–3), and 28 (57.1%) underwent more than one PIPAC procedure. Median PCI at the first PIPAC was 19 (15–22). PCI decreased for 37%, remained stable for 29.6%, and increased for 33.4% patients. Four (8.3%) underwent radical R0 surgery after PIPAC. After a median follow-up of 16.1 months (1.5–90.1), the median overall survival from PC diagnosis was 29.1 months (14.8–34.3), with a median gastric and colorectal PC survival of 11.3 (7.2–34.3) and 29.1 months (16.1–31) respectively. Overall survival after the first PIPAC session was 11.6 months (6–17.3), with median survival after gastric and colorectal PCs being 6 (2.9–15.5) and 13.3 months (5–17.6), respectively. Stratification of patients according to the number of lines of systemic chemotherapy, PIPAC procedures, and the chronology of PC onset did not result in a significant difference in survival. Conclusion: The OS was in line with the literature. PIPAC could delay oncological progression and improve survival. These encouraging results justify the ongoing and future evaluations of PIPAC by prospective randomized trials. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model

Author

Brusset, Bleuenn, primary, Dumortier, Jerome, additional, Cherqui, Daniel, additional, Pageaux, Georges-Philippe, additional, Boleslawski, Emmanuel, additional, Chapron, Ludivine, additional, Quesada, Jean-Louis, additional, Radenne, Sylvie, additional, Samuel, Didier, additional, Navarro, Francis, additional, Dharancy, Sebastien, additional, and Decaens, Thomas, additional

Published
2021
Full Text
View/download PDF

49. An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial.

Author

UCL - SSS/DDUV/GECE - Génétique cellulaire, Charles, Julie, Chaperot, Laurence, Hannani, Dalil, Bruder Costa, Juliana, Templier, Isabelle, Trabelsi, Sabiha, Gil, Hugo, Moisan, Anaick, Persoons, Virginie, Hegelhofer, Harald, Schir, Edith, Quesada, Jean-Louis, Mendoza, Christophe, Aspord, Caroline, Manches, Olivier, Coulie, Pierre, Khammari, Amir, Dreno, Brigitte, Leccia, Marie-Thérèse, Plumas, Joel, UCL - SSS/DDUV/GECE - Génétique cellulaire, Charles, Julie, Chaperot, Laurence, Hannani, Dalil, Bruder Costa, Juliana, Templier, Isabelle, Trabelsi, Sabiha, Gil, Hugo, Moisan, Anaick, Persoons, Virginie, Hegelhofer, Harald, Schir, Edith, Quesada, Jean-Louis, Mendoza, Christophe, Aspord, Caroline, Manches, Olivier, Coulie, Pierre, Khammari, Amir, Dreno, Brigitte, Leccia, Marie-Thérèse, and Plumas, Joel

Abstract

The efficacy of immune checkpoint inhibitors has been shown to depend on preexisting antitumor immunity; thus, their combination with cancer vaccines is an attractive therapeutic approach. Plasmacytoid dendritic cells (PDC) are strong inducers of antitumor responses and represent promising vaccine candidates. We developed a cancer vaccine approach based on an allogeneic PDC line that functioned as a very potent antigen-presenting cell in pre-clinical studies. In this phase Ib clinical trial, nine patients with metastatic stage IV melanoma received up to 60 million irradiated PDC line cells loaded with 4 melanoma antigens, injected subcutaneously at weekly intervals. The primary endpoints were safety and tolerability. The vaccine was well tolerated and no serious vaccine-induced side effects were recorded. Strikingly, there was no allogeneic response toward the vaccine, but a significant increase in the frequency of circulating anti-tumor specific T lymphocytes was observed in two patients, accompanied by a switch from a naïve to memory phenotype, thus demonstrating priming of antigen-specific T-cells. Signs of clinical activity were observed, including four stable diseases according to IrRC and vitiligoïd lesions. Four patients were still alive at week 48. We also demonstrate the in vitro enhancement of specific T cell expansion induced by the synergistic combination of peptide-loaded PDC line with anti-PD-1, as compared to peptide-loaded PDC line alone. Taken together, these clinical observations demonstrate the ability of the PDC line based-vaccine to prime and expand antitumor CD8+ responses in cancer patients. Further trials should test the combination of this vaccine with immune checkpoint inhibitors.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results